Front & Back Matter
Paweł Krawczyk, Gabriel Benz, Andrew J. H. Simpson(University of Hull), Asım Kalkan(Fırat University), Shin-ichi Yokota, Tamaki Okabayashi(University of Miyazaki), Paul Schnitzler(Heidelberg University), Torahiko Okubo, Kinga Winiarczyk, Tomasz Kucharczyk, Üner Kayabaş(Inonu University), Radosław Mlak(Medical University of Lublin), Yasuo Ohkoshi, Mehmet Doğanay(Lokman Hekim Üniversitesi), Zheng Yu Zhan, Zülal Özkurt(Atatürk University), Piotr Jaśkiewicz, Feng Miao(Collaborative Innovation Center of Advanced Microstructures), Kamila Wojas‐Krawczyk, Gökhan Metan(Hacettepe University), Hayrettin Akdeniz(Van Yüzüncü Yıl Üniversitesi), Akram Astani, Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Andreas Hochstrasser, Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Feng Qiu(Jilin University), Emine Parlak(Atatürk University), Janusz Milanowski(Asklepios Fachkliniken München-Gauting), Toyotaka Sato, Feng Yu(Xinjiang Production and Construction Corps), Ling Zhang(Hebei Medical University), Yutaka Tamura(Japan Medical Association), Han Xu(The University of Texas MD Anderson Cancer Center), Mehmet Parlak, Xiang Xiao, Yaşar Bayındır(Inonu University), Jian Zhao(Dana-Farber Cancer Institute), Jun Yan, Jia Li(Shanghai Institute of Materia Medica), Lei Guo, Hai-Di Sun, Nobuhiro Fujii, Osamu Kuwahara, Jürgen Reichling, Wen-Hua Tan, T Yi, Jing Guo(Hainan University), Quanxin Qu, Jian Xiong, Mustafa Kasım Karahocagil(Van Yüzüncü Yıl Üniversitesi)
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k